Activated T cells and soluble molecules in the portal venous blood of patients with cholestatic and hepatitis C virus-positive liver cirrhosis. Possible promotion of Fas/FasL-mediated apoptosis in the bile-duct cells and hepatocyte injury

Journal of International Medical Research

Volumn 31, Issue 3, 2003, Pages 170-180

  Ariki, N ^a   Morimoto, Y ^a   Yagi, T ^a   Oyama, T ^a   Cyouda, Y ^a   Sadamori, H ^a   Inagaki, M ^a   Urushihara, N ^a   Iwagaki, H ^a   Tanaka, N ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Apoptosis; Cholestatic liver cirrhosis; Fas; Fas ligand; HCV positive liver cirrhosis; Interleukin 18; Interleukin 6; Natural killer T cells

Indexed keywords

CYTOKINE; FAS ANTIGEN; FAS LIGAND; FASL PROTEIN; INTERLEUKIN 18; INTERLEUKIN 6; MEMBRANE PROTEIN;

ADULT; APOPTOSIS; ARTICLE; BILE DUCT; BILE DUCT INJURY; BLOOD; CHILD; CHOLESTASIS; CHOLESTATIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEEDBACK SYSTEM; FEMALE; FLOW CYTOMETRY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOLOGY; INFANT; LIVER CELL; LIVER CELL DAMAGE; LIVER CIRRHOSIS; LIVER FAILURE; LYMPHOCYTE ACTIVATION; MALE; METABOLISM; NATURAL KILLER CELL; PATHOLOGY; PERIPHERAL VEIN; PORTAL VEIN; PORTAL VEIN BLOOD; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

ADULT; ANTIGENS, CD95; APOPTOSIS; BILE DUCTS; CHOLESTASIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FAS LIGAND PROTEIN; FEMALE; FLOW CYTOMETRY; HEPATITIS C; HEPATOCYTES; HUMANS; INFANT; INTERLEUKIN-18; INTERLEUKIN-6; KILLER CELLS, NATURAL; LIVER CIRRHOSIS; LYMPHOCYTE ACTIVATION; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PORTAL VEIN;

EID: 10744226853     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000303100302     Document Type: Article

References (54)

1. Ferraz JG, Wallace JL: Underlying mechanisms of portal hypertensive gastropathy. J Clin Gastroenterol 1997; 25 (Suppl 1): 73-78.
2. Balistreri WF, Grand R, Hoofnagle JH: Biliary atresia. Current concepts and research directions. Summary of a symposium. Hepatology 1996; 23: 1682-1692.
3. Park WH, Kim SP, Park KK: Electron microscopic study of the liver with biliary atresia and neonatal hepatitis. J Pediatr Surg 1996; 31: 367-374.
4. Yagi T, Iwagaki H, Urushihara N, Kobashi K, Nakao A, Matsukawa H, et al: Participation of IL-18 in human cholestatic cirrhosis and acute rejection. Analysis in living donor liver transplantation. Transplant Proc 2001; 33: 421-425.
5. Rosen HR, Martin P: Hepatitis C infection in patients undergoing liver transplantation. Transplantation 1998; 66: 1612-1616.
6. Charlton M, Seaberg E, Wiesner R, Everhart J, Zetterman R, Lake J: Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28: 823-830.
7. Desmet VJ: Congenital diseases of intrahepatic bile ducts. Variations on the theme 'ductal plate malformation'. Hepatology 1992; 16: 1069-1083.
8. Tan CE, Driver M, Howard ER: Extrahepatic biliary atresia. A first-trimester event? Clues from light microscopy and immunohistochemistry. J Pediatr Surg 1994; 29: 808-814.
9. Morecki R, Glaser JH, Cho S: Biliary atresia and reovirus type 3 infection. N Engl J Med 1982; 307: 481-484.
10. De Maria R, Testi R: Fas-FasL interactions. A common pathogenetic mechanism in organ-specific autoimmunity. Immunol Today 1998; 19: 121-125.
11. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM: FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995; 81: 505-512.
12. Graham AM, Dollinger MM, Howie SEM, Harrison DJ: Bile duct cells in primary biliary cirrhosis are primed for apoptosis. Eur J Gastroenterol Hepatol 1998; 10: 553-557.
13. Strater J, Moller P: Pathogenesis of primary biliary cirrhosis. CD95-induced apoptosis at last? Eur J Gastroenterol Hepatol 1998; 10: 539-541.
14. Dienes HP, Lohse AW, Gerken G, Schirmacher P, Gallati H, Lohr HF: Bile duct epithelia as target cells in primary biliary cirrhosis and primary sclerosing cholangitis. Virchows Arch 1997; 431: 119-124.
15. Hiramatsu N, Hayashi N, Katayama K, Mochizuki K, Kawanishi Y, Kasahara A, et al: Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. Hepatology 1994; 19: 1354-1359.
16. Galle PR, Hofmann WJ, Walczak H, Schaller H, Otto G, Stremmel W, et al: Involvement for the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 1995; 182: 1223-1230.
17. Piazzolla G, Tortorella C, Fiore G, Serrone M, Caccetta L, Jirillo E, et al: Immunoresponsiveness in chronic hepatitis C patients. Correlation between tissue and serum findings. Immunopharmacol Immunotoxicol 1998; 20: 337-354.
18. Gavrieli Y, Sherman Y, Ben-Sasson SA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992; 119: 493-501.
19. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y: Lethal effect of the anti-Fas antibody in mice. Nature 1993; 364: 806-809.
20. Okazaki M, Hino K, Fujii K, Kobayashi N, Okita K: Hepatic Fas antigen expression before and after interferon therapy in patients with chronic hepatitis C. Dig Dis Sci 1996; 41: 2453-2458.
21. Nakanuma Y, Ohta G, Kono N, Kobayashi K, Kato Y: Electron microscopic observation of destruction of biliary epithelium in primary biliary cirrhosis. Liver 1983; 3: 238-248.
22. Kuroki T, Seki S, Lkawakita N, Nakatani K, Hisa T, Kitada T, et al: Expression of antigens related to apoptosis and cell proliferation in chronic nonsuppurative destructive cholangitis in primary biliary cirrhosis. Virchows Arch 1996; 429: 119-129.
23. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S: Lymphoproliferative disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992; 356: 314-317.
24. Bannai M, Kawamura T, Naito T, Kameyama H, Abe T, Kawamura H, et al: Abundance of unconventional CD8+ natural killer T cells in the large intestine. Eur J Immunol 2001; 31: 3361-3369.
25. Ishigaki M, Nishimura H, Naiki Y, Yoshioka K, Kawano T, Tanaka Y, et al: The roles of intrahepatic Va14+NK1.1+ T cells for liver injury induced by Salmonella infection in mice. Hepatology 1999; 29: 1799-1808.
26. Koneko Y, Harada M, Kawano T, Yamashita M, Shibata Y, Gejyo, et al: Augmentation of Va14 NKT cell-mediated cytotoxicity by interleukin-4 in an autocrine mechanism resulting in the development of Concanavalin A-induced hepatitis. J Exp Med 2000; 191: 105-114.
27. Wilson SB, Kent SC, Patton KT, Orban T, Jackson RA, Exley M, et al: Extreme Th1 bias of invariant Va24JaQ T cells type 1 diabetes. Nature 1998; 391: 177-181.
28. Sumida T, Sakamoto A, Murata H, Makino Y, Takahashi H, Yoshida S, et al: Selective reduction of T cells bearing invariant Va24JaQ antigen receptor in patients with systemic sclerosis. J Exp Med 1995; 182: 1163-1168.
29. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Sato H, et al: Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Va14 NKT cells. Proc Natl Acad Sci U S A 1998; 95: 5690-5693.
30. Tagawa Y, Sekikawa K, Iwakura Y: Suppression of concanavalin A-induced hepatitis in IFN-gamma(-/-) mice, but not in TNF-alpha (-/-) mice: Role for INF-gamma in activating apoptasis of hepatocytes. J Immunol 1997; 159: 1418-1428.
31. Tagawa Y, Kakuta S, Iwakura Y: Involvement of Fas/Fas ligand system-mediated apoptosis in the development of concanavalin A-induced hepatitis. Eur J Immunol 1998; 28: 4105 - 4113.
32. Seino K, Kayagaki N, Takeda K, Fukao K, Okumura K, Yagita H: Contribution of Fas ligand to T cell-mediated hepatic injury in mice. Gastroenterology 1997; 113: 1315-1322.
33. Watanabe Y, Morita M, Akaike T: Concanavalin A induces perforin-mediated but not Fas-mediated hepatic injury. Hepatology 1996;24:702-710.
34. Kusters S, Gantner F, Kunstle G, Tiegs G: Interferon-gamma plays a critical role in T cell-dependent liver injury in mice initiated by concanavalin A. Gastroenterology 1996; 111: 462-471.
35. Mizuhara H, O'Neil E, Seki N, Ogawa T, Kusunoki C, Otsuka K, et al: T cell activation-associated hepatic injury: Mediation by tumor necrosis factors and protection by interlukin-6. J Exp Med 1994; 179: 1529-1537.
36. Toyabe S, Seki S, Iiai T, Takeda K, Shirai K, Watanabe H, et al: Requirement of IL-4 and liver NK1+ T cells for concanavalin A-induced hepatic injury in mice. J Immunol 1997; 159: 1537-1542.
37. Gantner F, Leist M, Lohse AW, Germann PG, Tiegs G: Concanavalin A-induced T-cell-mediated hepatic injury in mice: The role of tumor necrosis factor. Hepatology 1995; 21: 190-198.
38. Gantner F, Leist M, Kusters S, Vogt K, Volk HD, Tiegs G: T cell stimulus-induced crosstalk between lymphocytes and liver macrophages results in augmented cytokine release. Exp Cell Res 1996; 229: 137-146.
39. Kusters S, Tiegs G, Alexopoulou L, Pasparakis M, Douni E, Kunstle G, et al: In vivo evidence for a function role of both tumor necrosis factor (TNF) receptors and transmembrane TNF in experimental hepatitis. Eur J Immunol 1997; 27: 2870-2875.
40. Ksontini R, Colagiovanni DB, Josephs MD, Edwards CK, III, Tannahill CL, Solorzano CC, et al: Disparate roles for TNF-α and Fas ligand in concanavalin A-induced hepatitis. J Immunol 1998; 160: 4082-4089.
41. Mariani SM, Matiba B, Baumler C, Krammer PH: Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases. Eur J Immunol 1995; 25: 2303-2307.
42. Cascino I, Fucci G, Papoff G, Ruberti G: Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol 1995; 154: 2706-2713.
43. Tanaka N, Suda T, Haze K, Nakamura N, Sato K, Kimura F, et al: Fas ligand in human serum. Nat Med 1996; 2: 317-322.
44. Taieb J, Mathurin P, Poynard T, Gougerot-Pocidalo MA, Chollet-Martin S: Raised plasma soluble Fas and Fas-ligand in alcoholic liver disease. Lancet 1998; 351: 1930-1931.
45. Frago LM, Paneda C, Fabregat I, Varela-Nieto I: Short-chain ceramide regulates hepatic methionine adenosyltransferase expression. J Hepatol 2001; 34: 192-201.
46. Camargo CA, Jr, Madden JF, Gao W, Selvan RS, Clavien PA: Interleukin-6 protects liver against warm ischemia/reperfusion injury and promotes hepatocyte proliferation in the rodent. Hepatology 1997; 26: 1513-1520.
47. Peters M, Blinn G, Jostock T, Schirmacher P, Meyer zum Buschenfelde KH, Galle PR, et al: Combined interleukin-6 and soluble interleukin-6 receptor accelerates liver regeneration. Gastroenterology 2000; 119: 1663-1671.
48. Dao T, Ohashi K, Kayano T, Kurimoto M, Okamura H: Interferon-β-inducing factor, a novel cytokine, enhances Fas ligand-mediated cytotoxicity of murine T helper 1 cells. Cell Immunol 1996; 173: 230-235.
49. Okamura H, Tsutsui H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, et al: Cloning of a new cytokine that induces IFN-β production by T cells. Nature 1995; 378: 88-91.
50. Stoll S, Muller G, Kurimoto M, Saloga J, Tanimoto T, Yamauchi H, et al: Production of IL-18 (IFN-β-inducing factor) messenger RNA and functional protein by murine keratinocytes. J Immunol 1997; 159: 298-302.
51. Stoll S, Jonuleit H, Schmitt E, Muller G, Yamauchi H, Kurimoto M, et al: Production of functional IL-18 by different subtypes of murine and human dendritic cells (DC). DC-derived IL-18 enhances IL-12-dependent Th1 development. Eur J Immunol 1998; 28: 3231-3239.
52. Conti B, Jahng JW, Tinti C, Son JH, Joh TH: Induction of interferon-γ-inducing factor in the adrenal cortex. J Biol Chem 1997; 272: 2035-2037.
53. Conti B, Park LC, Calingasan NY, Kim Y, Kim H, Bae Y, et al: Cultures of astrocytes and microglia express interleukin 18. Brain Res Mol Brain Res 1999; 67: 46-52.
54. Urushihara N, Iwagaki H, Yagi T, Kohka H, Kobashi K, Morimoto Y, et al: Elevation of serum interleukin-18 levels and activation of Kupffer cells in biliary atresia. J Pediatr Surg 2000; 35: 446-449.